New combo aims to outsmart Drug-Resistant leukemia
NCT ID NCT03513562
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding venetoclax to ibrutinib can eliminate resistance mutations in people with chronic lymphocytic leukemia (CLL) who have developed resistance to ibrutinib alone. The study enrolls 28 participants who are already taking ibrutinib and have a known resistance mutation. The goal is to see if the combination can make the cancer mutation-free after 12 treatment cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and ibrutinib
What this could lead to
If successful, this combination could help CLL patients overcome resistance to ibrutinib, potentially leading to longer remission without the need for stronger treatments.
What could go wrong
This is a small, early-phase study with only 28 participants, so results may not apply to all patients. The combination may cause side effects or fail to clear mutations in some people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States